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Abstract
Objective: To assess if patients treated with omega-3(n-3) polyunsaturated fatty acids (PUFAS) 
had lower procedural failure rates compared to an untreated population.                           
Methods and Results: From January 2004 to 2007, 1500 PVAI patients underwent catheter 
ablation. Two hundred and eighty five (19%) patients were treated with PUFAs.  These patients 
were matched in a nested case controlled analysis. After matching, there were 129 patients in the 
PUFA group and 129 in the control group. Thirty-five (27.1%) patients in the study group had 
early recurrence vs. 57 (44.1%) in the control group p-value<0.0001. Twenty-nine (23.2%) 
patients in the PUFA group vs. 41 (31.7%) in the non-PUFA group had procedural failure (p-
value <0.003). There were no significant differences in complications in the PUFA and non-
PUFA   groups.                                                                                
Conclusion:  Patients treated with PUFAs had lower incidences of early recurrence and 
procedural failure compared to an untreated population.                                                               
Key words:  Polyunsaturated Fatty acids (PUFA); Atrial Fibrillation (AF); Pulmonary vein 
isolation (PVAI)                                                                                                                 
Introduction
Pulmonary vein antrum isolation (PVAI) is a promising treatment for drug refractory atrial 
fibrillation (AF). Nevertheless, some patients have unsuccessful ablations.   Therefore, any 
supplemental agent that may increase the likelihood of success is of particular clinical and 
economic   interest.                                                                                        
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Prior studies have suggested that increased fish consumption may lower blood pressure, reduce 
systemic inflammation, reduce postoperative AF after coronary artery bypass surgery and 
improve left ventricular function, all of which result in a lower incidence of AF [1-9]. The active 
agent in fish oils is widely accepted to be omega-3(n-3) polyunsaturated fatty acids (PUFAs).     
This study investigated if patients that underwent catheter ablation had better success rates if 
they were treated with PUFAs.                                                                                   
Methods
Patient Population                                                                                                       
We screened 1,500 consecutive patients who had undergone PVAI at St David’s Medical Center 
Austin, Texas for PVAI from January 1, 2004 to January 1, 2007. Patients were divided into 
those treated with PUFAs vs. untreated.  Patients were then matched in a nested case controlled 
methodology to limit confounders.                                                                                 
                                               
Patients in the study population consumed PUFAs 1 month prior to PVAI and continued PUFAs 
during the entire follow-up period. Since there is no evidence of a preferred PUFA dose for 
PVAI, we included all patients who consumed a minimum of 655 mg of fish oil capsules. The 
control population had not consumed PUFAs prior PVAI or during the follow-up period. Atrial 
fibrillation was classified according to the guidelines for catheter ablation [10]. Early recurrence 
was defined as occurrences of AF during the initial 8 week interval post ablation (blanking 
period).  Procedural failure was defined as any recurrence of AF after 8 weeks from the time of 
the   procedure.                                                                                                
The study was predominantly retrospective, however; data were collected prospectively and 
housed in a computerized database. The study has institutional board review permission. All 
patients gave consent.                                                                                                
CRP   levels                                                                                                    
Baseline blood samples were obtained early in the day after an overnight fast. Plasma and serum 
levels were collected. Personnel blinded to clinical data performed CRP (C-reactive proteins) 
measurements. An ultrasensitive Enzyme Linked Immuno Sorbent Assay (ELISA) was used to 
measure CRP. The interassay coefficient of variation is 5.5%. Pre CRP levels were obtained no 
earlier than 1 month prior to the procedure. Post CRP levels were routinely collected 48 hours 
after the procedure.                                                                                                               
Ablation   Protocol                                                                                        
Prior to Ablation                                                                                                     
Antiarrhythmic drugs were discontinued four to five half-lives prior to ablation. Patients on 
amiodarone discontinued the medication 5 to 6 months prior to ablation. Some patients with 
persistent or longstanding persistent AF had a transesophageal echocardiography (TEE) or were 
treated with warfarin for approximately 5-6 weeks before the procedure. Warfarin was stopped 
2-3 days prior to the procedure and bridged with half dose of low molecular weight heparin.  
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Ablation   Procedure                                                                                    
All patients underwent the ablation procedure using the same ablation strategy. The details of the 
ablation procedure have been presented elsewhere [11]. Briefly, our ablation strategy included 
PVAI guided by circular mapping catheter (Lasso-Biosense/Webster, Diamond Bar California) 
and intracardiac echocardiography (Acuson, Seimens, Mountain View California, Ca) along 
with empirical isolation of superior vena cava. In patients with paroxysmal AF, the pulmonary 
vein antra and a portion of the posterior wall that is contained within the area of the 4 pulmonary 
veins were targeted. In non-paroxysmal, the entire posterior wall extending down to the coronary 
sinus was targeted. In addition, lesions were also delivered on the left side of the septum. 
Elimination of fractionated potentials in the right atrium, left atrium and coronary sinus was 
performed.  Radiofrequency energy was delivered with a 3.5 mm open irrigated tip catheter 
(Biosense/ Webster). As a final step in all procedures, patients had an electrophysiology study 
with and without high dose isoproterenol challenge (20-30 mcg/min).                                 
Anticoagulation
A heparin bolus (100-150U/kg) was given before transseptal punctures. The infusion rate was 
adjusted to keep activated clotting time (ACT) between 350-450 seconds. After PVAI, heparin 
was discontinued, and IV protamine 10 to 15 mg was given. Sheaths were pulled when ACT was 
<280 seconds. At the end of all procedures, patients were given oral 325 mg of aspirin prior to 
leaving the EP laboratory. Oral anticoagulation with warfarin was resumed on the same night of 
the procedure. Half dose of subcutaneous low-molecular-weight heparin was administered twice 
a day until the international normalized ratio (INR) was ≥2.   Patients after June of 2005 
continued their usual warfarin dose without preablation discontinuation while maintaining an 
INR between 2 to 3.5.                                                                                                       
Follow-up
All patients were discharged on oral anticoagulation therapy (warfarin) and in most cases 
antiarrhythmic medications. Follow-up was scheduled at 3, 6, 9 and 12 months after the 
procedure   and   every   six   months   henceforth.   Anticoagulation   and   antiarrhythmics   were 
discontinued in accordance to physician's discretion. At all the participating centres, nurses 
asked patients about PUFA consumption at each follow-up visit. If patients were unable to be 
seen, their status and PUFA consumption was assessed by a nurse practitioner via the telephone 
and monitoring tests were obtained by the referring physician. During the first 5 months after 
ablation, cardiac event monitoring was used to detect AF recurrence. Patients were asked to 
transmit their rhythm status three times a day and when they experienced symptoms consistent 
with AF.  In addition, 48- hour Holter monitoring was performed at 3, 6, 9 and 12 months and 
every 6 months thereafter.                                                                                        
Statistical   Analysis                                                                                      
The data from the case controlled control and study population were analyzed using SAS 
(version 9.2, Cary, NC). Patients were matched for type of AF, age, gender, left atrial size, 
ejection fraction, diabetes type II, hypertension, coronary artery disease, and stroke. Univariate 
analysis was performed and the mean ± standard deviation was reported for the continuous 
variables. Frequency analysis was conducted for the categorical variables and goodness of fit 
was performed to test if the frequency distribution fits the expected distribution. Student's t-test 
was used to compare the means across the populations. Recurrence-free survival over time was 
calculated by Kaplan-Meier method. P-value of less than 0.05 was considered statistically 
significant. 
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Results
Patient   Characteristics                                                                        
Two hundred and eighty-five out of 1,500 patients that underwent catheter ablation were treated 
with PUFAs (19%). One hundred and twenty-nine PUFA patients and 129 non-PUFA patients 
were matched for the control group. The case-controlled PUFA group had lower baseline and 
postablation   CRP   levels.                                                                                
Thirty-five (27.1%) patients in the study group had early recurrence vs. 57 (44.1%) in the 
control group p-value<0.0001. Twenty-nine (23.2%) patients in the PUFA group vs. 41 (31.7%) 
in the non-PUFA group had procedural failure (p-value <0.003). Kaplan Meier curve was 
constructed to depict the number of patients that were arrhythmia free at the end of the follow up 
period (mean 28+/7 months) given in  Figure 1.   There were no significant differences in 
complications between the PUFA and non-PUFA groups (Table 1). 
Figure 1: Kaplan Meier survival curve depicting the number of patients in each group that were arrhythmia free at 
the   end   of   the   follow-up   period.                                                                                    
Discussion
This is the first study that assessed the benefit of treatment with PUFAs in patients that had 
undergone catheter ablation. The main findings of our study were: 1) Patients treated with PUFAs 
had lower incidences of early recurrence and procedural failure rates. 2) Patients treated with 
PUFAs had significantly lower pre and post CRP levels. 3) Patients treated with PUFAs had 
similar complication rates as the control population.                                                                     
We observed that the anti-inflammatory properties of PUFAs appeared to be able to reduce the 
amount of inflammation thus, possibly lowering the incidence of early recurrence in patients that 
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had undergone catheter ablation. Calo et al. conducted a randomized controlled trial that 
demonstrated that oral intake of PUFAs for at least 5 days prior to CABG reduced the incidence of 
postoperative AF by 54.4% [5]. While our success rates were not as dramatic as that reported by 
Calo et al., our study also demonstrated improvement in recurrence of AF postoperatively. 
Additionally, many of Calo's patients did not have a prior history of AF thus, they most likely did 
not have a complex pre-existing atrial substrate perpetuating AF.
Table 1: Demographics of the case controlled study and control populations
We observed that patients on PUFAs had less procedural failure rates than the control group.  
Mozaffarin et al. conducted a prospective, population-based cohort study of 4,815 adults who 
consumed tuna or other broiled or baked fish illustrating the association between PUFA 
consumption and lower incidences of AF [4].                                                 
Prior studies had reported that PUFAs consumption reduces incidence of strokes [7]. He et al in a 
prospective cohort study with 43,671 subjects showed that consuming 1 or more servings of fish 
reduce the risk of stroke in men during a 12 year follow-up [8].  Bouzan et al conducted a meta-
analysis demonstrating that any fish consumption confers substantial relative risk   reduction 
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compared to no fish consumption [9]. We observed no benefit in postprocedural stroke in our 
population.   
Limitations
While our study reported new findings, it was limited because it was a small retrospective study 
thus, had all the limitations inherent to a study of this design. However, all data were 
prospectively collected. We did not have information about patient dietary fish consumption; 
nevertheless, we have no reason to suspect that dietary intake was substantially different between 
subjects. We were not able compare the affects of variations in dosages because the groups would 
be too small for correct analysis.                                                                                   
Conclusion
Patients treated with PUFAs had a lower incidence of early recurrence and procedural failure.     
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